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Patient 1. A 25-year-old black Brazilian male first went to the
emergency room of Hospital São Paulo when he was 9 years old,
complaining of weight loss, excessive hunger, and polydipsia and
polyuria for 10 days. The diagnosis of diabetic ketoacidosis was made.
The patient was treated appropriately and referred to the Diabetes
Clinic. He was treated with NPH insulin, 20 units subcutaneously daily.
At age 23 he was seen for the first time in the Hypertension-Diabetes
Clinic, at which time he was taking NPH insulin (75 units in the morning
and 20 units in the evening), Since the diabetes had been diagnosed, he
had had 15 hospital admissions because of ketoacidosis. He complained
sporadically of paresthesias of the legs, and his vision had deteriorated
considerably over the previous 2 years. No history of edema or diarrhea
was elicited, nor were symptoms of postural hypotension or sexual
impotence present, He did not smoke or abuse alcohol. He exercised
twice weekly. The patient's father and mother had non-insulin-depen-
dent diabetes mellitus and hypertension. Data from the patient's
hospital records are contained in Table 1.
Physical examination revealed: weight, 64.5 kg; height, 168 cm; body
mass index, 22.85 kg/rn2. The supine blood pressure was 134/88 mm Hg,
and the heart rate was 88 beats/mm. The orthostatic blood pressure was
132/98 mm Hg; heart rate, 94 beats/mm. Funduscopy disclosed prepro-
liferative retinopathy with cotton-wool exudates in regression and hard
exudates in the fovea and macular region.
Laboratory data disclosed: fasting blood glucose, 111 mg/dl; glyco-
sylated hemoglobin, 8.3%; plasma creatinine, 0.7 mg/dl; plasma potas-
sium, 5.1 mEq/liter; plasma sodium, 146 rnEq/liter; urinary protein
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excretion, 0.6 g/24 hours; urinary glucose excretion, 27 g/24 hours.
Microscopic examination of the urine was normal. Creatinine clearance
was 150 mllmin, and renal plasma flow (RPF by '311-Hippuran) was 1325
ml/min. Values for 12-hour albumin excretion from three nocturnal
collections during the first week of followup were: 723, 367, and 357
g/mmn. The patient was maintained on insulin, and chlorthalidone, 25
mg/day, was introduced because of mild hypertension. Six months
later, proteinuria was 1.8 g/24 hours, the upright blood pressure had
risen to 150/100 mm Hg, the glomerular filtration rate (by 51Cr EDTA)
was 190 ml/min/l.73 m2, and the renal plasma flow was 961 mllmin/1.73
m2. Chlorthalidone was replaced by nitrendipine, 10 mg twice daily.
The blood pressure was controlled and the urinary protein excretion
diminished slightly. Three months later, his upright blood pressure was
130/80mm Hg; proteinuria, 1.4 g/24 hr; GFR, 164 ml/min/l.73 m2; and
renal plasma flow, 1186 ml/min/l .73 m2. Nitrendipine was discontinued
because of side effects, and captopril, 25 mg twice daily, was introduced
as the sole antihypertensive agent. Another evaluation 4 months after
the introduction of captopril revealed: upright blood pressure, 132/76
mm Hg; proteinuria, 2.8 g/24 hr; GFR, 183 ml/min/1.73 m2; and renal
plasma flow, 1171 mI/mm/i .73 m2. Other laboratory data included 25
dysmorphic red cells/high-power field on urine microscopy, and a
plasma creatinine of 1.0 mg/dl.
Patient 2. A 36-year-old white Brazilian male with insulin-dependent
diabetes mellitus for 11 years complained of frequent episodes of
dizziness and dark vision when he stood during the previous year.
Postural hypotension was diagnosed, and he came to the Diabetes
Clinic of Escola Paulista de Medicina for treatment. He denied the use
of any medication known to cause postural hypotension. He had been
followed by an ophthalmologist for visual loss due to proliferative
diabetic retinopathy, and he had several sessions of laser photocoagu-
lation. He also had frequent episodes of nocturnal diarrhea, sexual
impotence, and paresthesias in his legs. He denied chest pain, smoking,
and alcohol abuse. His current daily medications were: NPH insulin, 45
units in the morning and 10 units in the evening; pancreatic enzymes, 8
capsules; and vitamin B complex, 2 capsules. The body weight was 67
kg; height, 180 cm; supine blood pressure and heart rate, 140/85 mm Hg
and 80 beats/mm; and upright blood pressure and heart rate, 100/70 mm
Hg and 88 beats/mm, respectively. Physical examination was otherwise
unremarkable except for severe impairment of vision, diminished tactile
and pain sensation in his legs, and retinal scars due to photocoagulation.
Laboratory data included: fasting plasma glucose, 128 mg/dl; plasma
creatinine, 0.6 mg/dl; BUN, 16 mg/dl; urinary protein excretion, 0.07
g/24 hours; and urinary glucose excretion, 4.5 g/24 hr. An electrocar-
diogram revealed an inactive anteroseptal region, and a vectorcardio-
gram was normal, as was a chest radiograph. The patient was then
enrolled in an experimental protocol to test the clinical usefulness of
domperidone, a D2 dopaminergic receptor antagonist, for the treatment
of hypotension. While in the hospital, he was fed a daily diet containing
150 mEq of sodium and was given domperidone (30 mg/daily). Three
days after the treatment began, the supine blood pressure levels were
not altered, but the postural hypotension remitted significantly (before
treatment, upright blood pressure after 30 minutes of standing was 75/60
mm Hg; after treatment, it was 115/78 mm Hg). This improvement in
blood pressure was accompanied by an increase in ereatinine clearance
and fractional sodium excretion in the upright posture, both of which
were severely diminished before domperidone treatment. The patient
was followed in our clinic for one year, during which the supine (S) and
upright (U) blood pressures (mm Hg) during domperidone treatment
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Table 1. Clinical and laboratory data from Patient I
1977 1987
(age 12 years) 1980 1982 1985 (age 22 years)
Blood pressure 120/60 120/80 120/82 130/82 130/86
(mm Hg)
Urinary protein neg neg neg 0.32 0.21
(g/24 hrs)
Urinary albumin — — — — 96 & 72
(ag/min)
Plasma creatinine 0.5 0.8 0.9 0.7 0.8
(mg/dl)
Funduscopy nI nI nl nI background
retinopathy
were measured (Table 2). He needed no other treatment for postural
hypotension during this followup period, and he had a significant
amelioration of orthostatic symptoms throughout.
Discussion
DR. ARTUR B. RIBEIR0 (Professor of Medicine, Disciplina de
Nefrologia, Escola Paulista de Medicina, São Paulo, Brazil):
The first patient is an insulin-dependent diabetic who developed
diabetic nephropathy with a concomitant rise in systemic blood
pressure without a measurable decline in overall renal function.
The fact that his hypertension and diabetic nephropathy, as
assessed by increasing amounts of urinary protein, progressed
without a measurable decrease in renal function underscores
the complex relationship of increased systemic blood pressure
and diabetic renal disease; the various antihypertensive regi-
mens he received reflect some of our current therapeutic
dilemmas. On the other hand, the second patient also has
insulin-dependent diabetes without evidence of clinical diabetic
nephropathy, but he developed postural hypotension, another
systemic blood pressure dysfunction of diabetic patients. Fi-
nally, both patients have diabetic retinopathy, a microvascular
complication of diabetes also closely related to systemic blood
pressure levels. I will review some clinical problems posed by
systemic blood pressure derangements in diabetes, and I will
focus mainly on insulin-dependent diabetes mellitus.
Epidemiology. Hypertension frequently is associated with
both non-insulin-dependent diabetes mellitus (NIDDM) and
insulin-dependent diabetes mellitus (IDDM). Hypertension in
patients with NIDDM occurs twice as frequently as in the
general population [1, 2], although lower prevalence rates have
been reported [3]. In this population, hypertension is not related
to the presence of clinical nephropathy, which occurs in ap-
proximately 15% of patients with NIDDM. Nephropathy ap-
pears to be more frequent in elderly than in younger NIDDM
patients. A study of a well-defined population aged 60 to 74
years clearly showed that microalbuminuria was twice as com-
mon in males with occult fasting hyperglycemia than in appro-
priate age-matched, normoglycemic controls with similar levels
of systolic blood pressure [4]. The frequency of microalbumin-
uria in these patients was comparable to that seen in male and
female patients with known NIDDM. Indeed, increased mi-
croalbuminuria (versus controls) in these elderly males with
occult fasting hyperglycemia, who could be classified as having
NIDDM by a glucagon-C-peptide test, was present even before
fasting hyperglycemia became clinically evident; we thus can
conclude that occult renal involvement is an early event in this
Table 2. Supine and upright blood pressure values in Patient 2
during domperidone therapy (mm Hg)
Baseline 10 days 30 d 60 d 120 d 180 d 300 d 360 d
S 148/80 138/88 110/70 120/75 130/90 155/100 150/88 140/85
U 80/70 100/75 85/60 100/70 100/80 110/82 120/90 110/70
a Metabolic diabetic decompensation. He needed no other treatment
for postural hypotension during this followup period, and he had a
significant amelioration of orthostatic symptoms throughout.
age group. In IDDM, on the other hand, hypertension generally
is restricted to patients with nephropathy, approximately 33%
of the population with IDDM [5]. In the past, hypertension in
diabetic patients was attributed to either concurrence of essen-
tial hypertension in NIDDM or to chronic renal failure in
IDDM. Even though no pathogenetic mechanism for the hyper-
tension associated with diabetes has been clearly established,
recent studies have considerably enhanced our knowledge
about the complex relationships among glucose homeostasis,
blood pressure regulation, and renal function in diabetes. Al-
though both types of diabetes have in common excess ex-
changeable sodium and increased vascular reactivity to pressor
agents [6], hypertension appears to evolve through different
mechanisms in NIDDM and IDDM. In NIDDM, insulin resis-
tance and hyperinsulinemia appear to contribute to the patho-
genesis of hypertension and also might link NIDDM, hyperten-
sion, obesity, and dyslipidemia [7]. However, older age and
obesity also seem to be partly responsible for the increased
prevalence of hypertension in NIDDM [3, 8].
Relationship to proteinuria. In IDDM, hypertension develops
in parallel with the clinical evolution of nephropathy, directly
correlates with urinary protein excretion [9], and inversely
correlates with creatinine clearance [10]. Hypertension in
IDDM therefore had been considered a consequence of clini-
cally established renal failure [11]. Thus, according to the old
view, loss of renal function and the ensuing development of
clinical renal insufficiency resulted in arterial hypertension, as
is usually the case for the primary renal diseases. Recent data
suggest, however, that this process is not applicable in the
insulin-dependent diabetic population. Thus normal renal func-
tion (as evaluated by clearance techniques) and minute amounts
of albumin in the urine, are common findings in the early stages
of hypertension in patients with IDDM. Indeed, several studies
have established that hypertension and microalbuminuria (that
is, urinary albumin excretion between 20 and 200 g/min) in
IDDM occur very early in the course of diabetic nephropathy,
when creatinine clearance is still normal and clinically evident
nephropathy is not apparent [12—14]. Experimental studies from
our group in streptozotocin-induced diabetes in rats are partic-
ularly relevant in analyzing the relationship between renal
dysfunction and hypertension. The administration of streptozo-
tocin (50 mg/kg intravenously) is accompanied by an increase in
tail arterial pressure that appears during the first week after
streptozotocin administration and lasts throughout the 6 months
of observation (Fig. 1). This increase is higher when the
animals' diabetes is not treated (closed circles) than when their
diabetes is partially controlled by a daily dose of 2 mU of insulin
(open circles), but hypertension occurs in both the untreated
and partially treated groups. In this model, plasma creatinine is
normal until the third week, when it begins to rise progressively
E
E
a-
I-
(0.8 0.04 mg/dl, 0.94 0.21, 1.1 0.05, 1.5 0.09, for
control, 3rd, 6th, and 12th weeks after induction of diabetes,
respectively, P < 0.05 as of the 6th week, n = 9) [15]. Anatomic
glomerular damage in our experience, as assessed by both light
and electron microscopy, occurs only at the 12th week, when a
diffuse increase in mesangial matrix and some degree of hyper-
cellularity are observed in these animals [15]. Thus, although
measurable renal dysfunction appears as of the 6th week,
hypertension already is present by the second week, when
plasma creatinine levels and glomerular histology are still in the
normal range. Thus in this experimental model, as well as in
humans, hypertension and increased urinary albumin excretion
appear to develop concomitantly and while renal excretory
function is still within normal limits.
The relationship between blood pressure and diabetic ne-
phropathy also was clarified in a study from our group [16]. We
grouped 69 patients with insulin-dependent diabetes according
to urinary albumin excretion (UAE) or urinary protein excre-
tion (UPE) (Table 3): normalbuminuric (UAE <20 jig/mm, n =
35), microalbuminuric (20 UAE < 200 p.g/min, n = 21), or
proteinuric (UPE > 0.5 g124 hours, n = 13). The three groups
did not differ significantly in age or duration of diabetes. Plasma
creatinine values were in the normal range and did not differ
statistically between the normalbuminuric and microalbumin-
uric groups. However, plasma creatinine values were higher in
the proteinuric group than in the normalbuminuric group.
Diastolic upright blood pressure increased in parallel with
increases in albumin and protein excretion. Thus diastolic blood
pressure was significantly higher in the microalbuminuric pa-
tients and was at even higher levels in the proteinuric patients.
Accordingly, a strong positive correlation between urinary
albumin excretion and mean arterial pressure was found in 63 of
the 69 patients (Fig. 2) [16]; this correlation also has been
demonstrated by others [9, 17, 18]. These results conform with
other studies in the literature that also report blood pressure
increases in the microalbuminuric phase of diabetic nephropa-
thy [14, 17]. Longitudinal studies confirm that blood pressure
does not increase with time in normalbuminuric patients but
does increase in those with microalbuminuria and even more so
in patients with clinical proteinuria [14, 19]. Accordingly, in one
series, none of the 31 patients who began the study with normal
Table 3. Age, duration of diabetes mellitus, plasma creatinine, and
diastolic blood pressure in 69 patients grouped according to urinary
albumin level or protein excretiona
Diastolic
Groups
Age
(years)
Diabetes
mellitus
(years)
Plasma
creatinine
(mg/dI)
blood
pressure
(mm Hg)
Normalbuminuric 23.8 7.1 8.1 5.8 0.7 0.1 77.8 8.2
(8.2 4.6 jig!
mm)
Microalbuminuric 23.2 7.9 9.6 5.7 0.8 0.2 b87.7 8.2
(55.8 38 jig!
mm)
Proteinuric 20.7 6.8 10.7 2.5 1.36 1.4C 98.7 6.I'
(1.76 2.5 gI
24 hr)
a Normalbuminuric, n = 35; microalbuminuric, n = 21; proteinuric,
n = 13. Values are mean SD. (Reproduced from Ref. 16 with
permission.)bP < 0.001, 2 versus I.
P < 0.01, 3 versus 1.
d P < 0.01, 3 versus 2.
e P <0.001, 3 versus 1.
UAE had clinically detectable proteinuria at the later examina-
tion, although 4 had microalbuminuria [14]. In the 27 patients
whose UAE did not increase, blood pressure levels (which were
in the normal range when the study began) also did not increase
during the followup period (initial: 124 7/80 8 mm Hg; final:
123 10/84 6 mm Hg). In contrast, 14 patients in the same
study had microalbuminuria (defined in this study as UAE from
15 to 150 jig/mm) at the beginning of the 7-year followup period.
Twelve of these 14 patients had clinically detectable proteinuria
(>500 mg/24 hours) at the end of the study. Blood pressure
increased in parallel with the UAE: from 138 19/89 6 mm
Hg to 149 18/99 12 mm Hg, P < 0.01, in the 9 patients
whose initial UAEs were <70 jig/mm; and from 137 6/97 7
mm Hg to 163 6/113 10 mm Hg, P < 0.01, in those with
initial UAEs >70 jig/mm. In another study, 12 patients with
insulin-dependent diabetes and overt diabetic nephropathy
(proteinuria > 0.5 g/24 hours) exhibited progressive and parallel
increases in arterial pressure and albumin excretion during the
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Fig. 1. Tail arterial pressure (TAP) in
streptozotocin-diabetic rats without (closed
circles) or with (open circles) insulin
treatment before (B) and as long as 24 weeks
after streptozotocin (STZ). Numbers for
STZ untreated group: 82(B-2w), 72(3-5W), 49(6-
I I I I I I I I I 11w), 21(12-17w), 11(18-24w) and for treated
B 2 4 6 8 10 12 14 16 18 20 22 24 group: 56, 47, 38, 23, 11, respectively. * = P
<0.05 versus B; * = P < 0.05 versus
Time, weeks insulin-treated.
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Fig. 2. Correlation between diastolic blood pressure (DBP) in the
upright posture and urinary albumin excretion (UAE) in insulin-
dependent diabetic patients. (Reproduced from Ref. 16 with
permission.)
24 months of followup in the first phase of the study, in which
no antihypertensive treatment was instituted [191. Urinary
albumin excretion diminished in 9 of the 10 effectively treated
patients during the second phase of the study, when antihyper-
tensive treatment was instituted. These findings demonstrate
that reversal of hypertension also reverses albumin excretion.
Genetic aspects. Several studies have suggested that the
development of renal disease in diabetic patients with IDDM is
associated with a genetic propensity for hypertension. Diabetic
nephropathy occurs in familial clusters: diabetic siblings of
patients with diabetic nephropathy show a higher frequency of
diabetic nephropathy than do diabetic siblings of diabetic
patients without nephropathy [20]. This genetic susceptibility is
further supported by the finding that diabetic nephropathy is
more common in patients whose nondiabetic parents have high
blood pressure [211 and from studies showing increased maxi-
mal velocity of sodium-lithium countertransport in red cells.
This finding, frequent in patients with essential hypertension, is
also common in diabetic patients with nephropathy. One study
compared erythrocyte sodium-lithium exchange in groups of
patients with IDDM plus nephropathy, IDDM without nephrop-
athy, and nephropathy without diabetes [221. Sodium-lithium
exchange was higher in erythrocytes of the patients with IDDM
plus nephropathy than in erythrocytes from diabetic patients
without renal disease or nondiabetic patients with renal disease.
In another study, patients with IDDM and nephropathy were
more likely to have a family history of hypertension, increased
blood pressure, and an increased maximal rate of erythrocyte
sodium-lithium exchange when compared with IDDM patients
with retinopathy or without complications [23]. This hypothesis
offers insights into why the association between nephropathy
and high blood pressure is so frequent and why nephropathy
only occurs in a proportion of patients with IDDM. However,
other investigators failed to show any difference in blood
pressure level or prevalence of hypertension between the
parents of diabetic patients with or without nephropathy [24] or
to demonstrate any particular difference in sodium-lithium
exchange between patients with IDDM with or without ne-
phropathy [25, 26]. It is currently unknown whether a small
elevation in blood pressure, even within the normal range,
could elicit microalbuminuria or whether microalbuminuria,
possibly through inducing glomerular damage, could elicit
blood pressure increases. Finally, it also is possible that these
events are concomitant and share an unknown causative factor.
Once initiated, the glomerular damage and blood pressure
elevation would tend to self-perpetuate. Thus the question of
whether elevation of blood pressure actually precedes [27] or is
concomitant with the appearance of incipient nephropathy [9,
12, 13, 28, 29] is currently unsettled.
Prevention of progressive renal failure by control of hyper-
tension. A major clinical issue at present is whether the
-a-— diminution of microalbuminuria by the administration of anti-
110 hypertensive agents in normotensive diabetic patients with
normal or supranormal GFR delays the appearance and pro-
gression of renal insufficiency. Such therapy already has been
shown to have a favorable effect on the course of hypertensive
patients with overt diabetic nephropathy [30, 31]. The presence
of persistent microalbuminuria (incipient nephropathy) strongly
predicts the development of macroproteinuria (defined as the
occurrence of persistent urinary albumin excretion above 200
ig/min or urinary protein excretion >0.5 g/24 hr). Macropro-
teinuria, also referred to as overt diabetic nephropathy, ulti-
mately evolves into uremia [13, 14, 32, 33]. Several studies have
demonstrated that antihypertensive treatment of a few months
reduces or prevents increases in microalbuminuria in normo-
tensive diabetic patients. These studies were performed for the
most part in patients with IDDM who were given angiotensin-
converting-enzyme (ACE) inhibitors alone [34, 35], ACE inhib-
itors in combination with a diuretic [36], or ACE inhibitors in
comparison with calcium-channel blockers [37, 381. Experi-
ences with antihypertensive agents in this population other than
ACE inhibitors, diuretics, and calcium-channel blockers have
not been published. Angiotensin-converting-enzyme inhibitors
almost invariably diminish urinary albumin excretion, although
one study reported no decrease in the presence of no changes or
small decreases in blood pressure [37]; one group claimed that
these agents lower albumin excretion irrespective of their
hypotensive effect [36]. On the contrary, calcium-channel
blockers increased [38] or did not change urinary albumin
excretion in normotensive microalbuminuric patients with
IDDM [37]. Conclusions as to whether the ACE-inhibitor-
induced reduction in urinary albumin excretion protects the
.
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kidney are not possible yet. In a one-year, randomized followup
study comparing an ACE inhibitor with a placebo, 3 of 10
microalbuminuric patients receiving a placebo, but none given
ACE-inhibitor therapy, developed overt nephropathy [39]. Gb-
merular filtration rate also was better preserved in the treated
group. Blood pressure levels, which were slightly higher than
normal at the beginning of the study, decreased in this group
during treatment but increased in the group given a placebo. A
4-year followup study in normotensive patients with incipient
nephropathy showed a reduction in the urinary excretion of
albumin in the treated patients (who received captopril plus a
thiazide), whereas albuminuria increased in the untreated group
[36]. Seven of 23 patients from the untreated group and none
from the treated group developed clinically overt nephropathy.
This study noted but failed to document a better preservation of
GFR in the treated group, however.
One major problem with these studies is that they frequently
mix normotensive with hypertensive patients or use a definition
of normotension that includes mildly hypertensive patients.
Furthermore, microalbuminuria frequently is followed by ele-
vation of blood pressure, so most studies enrolled patients as
normotensive who ended up as hypertensive by the end of the
study. Finally, small but measurable falls in arterial pressure
are frequently observed; these declines are not accounted for in
the study results, however. The meaning of increasing albumin-
uria in the absence of a documented decline in renal function is
not clearly established, nor is it known how low the level of
mean arterial pressure (MAP) must be to protect against dete-
rioration of renal function. So one cannot reach a definitive
conclusion from these studies. These studies do suggest, how-
ever, that ACE inhibition can postpone or even prevent pro-
gression to clinical overt nephropathy in normotensive patients
with IDDM who have microalbuminuria. Long-term followup
studies are needed to determine whether preservation of renal
function can be maintained in the patients whose microalbu-
minuria did not increase and whether maintaining normal or
subnormal levels of blood pressure through various antihyper-
tensive regimens can avoid or postpone progression of the
diabetic nephropathy.
When microalbuminuric patients with IDDM develop hyper-
tension, their renal function is still in the normal range. Several
antihypertensive regimens can lower blood pressure as well as
albumin excretion in such patients. They include: a beta blocker
in combination with a diuretic [40) or with an ACE inhibitor
[41], an ACE inhibitor alone [37], and calcium blockers [37].
Contrary to results in normotensive microalbuminuric patients,
calcium-channel blockers also decrease albumin excretion in
hypertensive microalbuminuric patients [37]. Our own experi-
ence confirms this finding (Table 4). In 5 hypertensive patients
with IDDM, the calcium-channel blocker nitrendipine, given for
12 weeks, decreased UAE from 58 31 to 32 19 /.Lg/min and
returned the blood pressure level to normal. Baba et a! de-
scribed a similar experience in hypertensive microalbuminuric
patients with NIDDM in whom ACE inhibitors and calcium-
channel blockers equally effectively controlled blood pressure
and diminished albumin excretion [42]. Prospective studies
have shown that prolonged reductions of arterial pressure with
conventional antihypertensive treatment reduces the rate of
decline in the glomerular filtration rate in hypertensive microal-
buminuric patients with IDDM [40, 431.
Table 4. Nitrendipine in patients with IDDM and nephropathy
Microal
(n
buminuric
=5) Clinical nephropathy(n=5)
Before After Before After
MAP Ill 4.0 98 45b 116 3.3 5b
(mm Hg)a
GFR 129 26 109 28" 155 36 119 371)
(mi/mm)
RPF 618 90 702 105b 700 172 823 252b
(mi/mm)
FF(%)
RVR
21±4
0.18 0.03
16÷3'
0.14 0.02"
22±3 152b
0.17 0.04 0.12 0.04"
(mm Hg!
mi/mm)
UPE — — 1.4 0.5 0.9 05b
(g/24 hr)
UAE 67.9 x/÷ 1.4 34 x/÷ 1.2" — —
(p.g/min)
HbAI (%) 8.8 1.0 9.0 1.7 8.3 0.7 8.9 1.8
Mean arterial pressure (MAP), glomerular filtration rate (GFR), renal
plasma flow (RPF), filtration fraction (FF), renal vascular resistance
(RVR), glycosylated hemoglobin (HbAl), urinary protein excretion(UPE), and urinary albumin excretion (UAE) were determined before
and after 12 weeks of nitrendipine therapy in patients with IDDM and
microalbuminuria or clinical nephropathy. Values are presented as
mean SD except for UAE, which is expressed by geometric mean
x/± confidence factor.
b P < 0.05.
When macroproteinuria appears in patients with IDDM,
treatment of hypertension is of paramount importance to slow
the decline of renal function that ensues. The development of
some degree of proteinuria in both IDDM and NIDDM in-
creases the frequency of small- and large-vessel disease, the
major cause of mortality and morbidity in diabetes [44, 45]. The
mortality rate in IDDM patients with diabetic nephropathy is
roughly 100 times higher than that of age- and gender-matched
controls in the general population [44]. Arterial hypertension
accelerates, and antihypertensive therapy reduces, the rate of
decline in the glomerular filtration rate, thereby postponing the
most common cause of death in patients with diabetic nephrop-
athy, end-stage renal failure [19, 311. This delay in the progres-
sion to end-stage renal failure originally was documented in
diabetic patients treated with conventional antihypertensive
treatment, usually diuretics, a beta blocker, and hydralazine.
The difference in the rate of the progression of the renal failure
was so evident that in 1987 the Working Group on Hypertension
in Diabetes advocated aggressive treatment of hypertension in
diabetic patients [46]; this approach has become established
medical practice for these patients.
Role of intraglomerular hypertension. Regarding pathogene-
sis, animal studies have implicated intragbomerular hyperten-
sion in the gbomerular injury of experimental diabetes [471 and
suggested that antihypertensive agents could differ in their
ability to delay renal damage according to their effect on
intraglomerular hemodynamics. In one animal model of diabetic
nephropathy, converting enzyme inhibition prevented glomer-
ular damage without effecting a documented decrease in sys-
temic blood pressure; this action was ascribed to correction
of intraglomerular hypertension [48]. These observations
prompted a series of human studies comparing the effects of
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various antihypertensive agents on systemic blood pressure and
renal hemodynamics in diabetic hypertensive patients. Table 4
shows our results with the calcium-channel-blocker nitren-
dipine, administered for 12 weeks to patients with IDDM and
microalbuminuria or clinical nephropathy. Nitrendipine signif-
icantly reduced mean arterial pressure (MAP) in both groups;
this decrease was accompanied by reductions in UAE and
protein excretion (UPE). Statistically significant correlations
were found between reductions in MAP and percent falls in
UAE (r = 0.83, P < 0.01) and UPE (r = 0.97, P < 0.01). Renal
plasma flow (RPF) increased, GFR decreased, and both filtra-
tion fraction (FF) and renal vascular resistance (RVR) de-
creased in both groups. These alterations in renal hemodynam-
ics are in accordance with the renal actions of calcium-channel
blockers, which are thought to cause a nonselective dilation of
afferent and efferent arterioles or a selective reduction of
preglomerular resistance [49]. Thus, nitrendipine diminished
UAE and UPE in association with a reduction in systemic
arterial pressure and by inference a diminution in glomerular
pressure. These observations conform with numerous reports
showing that antihypertensive agents produce a decrease in
protein excretion that parallels the fall in systemic pressure [19,
31, 50]. As I said before, according to some reports, calcium-
channel blockers actually might increase or not alter urinary
albumin excretion [38, 511. These effects of calcium-channel
blockers on urinary albumin excretion have been ascribed to a
deleterious action on intrarenal hemodynamics, namely, affer-
ent vasodilation, which increases intraglomerular pressure, or
to an inhibitory effect on proximal tubular transport including
albumin reabsorption. Other studies suggest, however, that
calcium-channel blockers also diminish urinary albumin or
protein excretion [37, 42, 52]. These reports support the view
that a decrease in systemic blood pressure is the main determi-
nant of the diminution of urinary protein excretion. Angioten-
sin-converting-enzyme inhibitors, on the other hand, diminish
urinary protein excretion in diabetic nephropathy indepen-
dently of changes in systemic blood pressure. This effect is
thought to be due to its beneficial intrarenal effect, namely,
inhibition of angiotensin 11-mediated vasoconstriction of the
efferent renal arteriole and diminution in intraglomerular pres-
sure [36, 48], and/or to a direct effect on the permeability of the
glomerular membrane [53]. Table 5 contains data from 6 mi-
croalbuminuric and 4 macroalbuminuric (clinical nephropathy)
patients with IDDM who were treated with captopril for 12
weeks. The only remarkable change in these groups during
captopril treatment was a statistically significant reduction in
urinary albumin excretion. No statistically significant changes
were observed in mean arterial pressure, glycosylated hemo-
globin, or renal parameters. However, individual MAP re-
sponses to captopril were very uneven (Fig. 3). In Figure 3,
patients are ordered according to their MAP response to the
captopril: in 5 patients, blood pressure fell; 3 had no change in
blood pressure; in 2, blood pressure increased. Albumin re-
sponses to captopril also are shown. No statistically significant
correlation was found between MAP and UAE changes for the
entire group or even considering only the 5 patients who
responded to captopril with decreases in MAP. This lack of
correlation contrasts sharply with the observed correlation for
nitrendipine and suggests that captopril lowers albumin excre-
tion by a mechanism other than blood pressure reduction.
Table 5. Captopril in patients with IDDM and nephropathy
Microalb
(n
uminuric
=6)
Clinical nephropathy
(n=4)
Before After Before After
MAP (mm 100 12.5 103 15.5 116 16.1 103 13.1
Hg)a
GFR(mi/ 124 26 134 49 111 37 97 12
mm)
RPF (ml! 648 198 667 201 643 219 671 152b
mm)
FF(%) 21±8 21±5 19±10 15±3
RVR (mm 0.18 0.08 0.17 0.05 0.19 0.04 0.16 0.06
Hg/mit
mm)
UAE (jig! 43.5 x/÷ 1.9 16.7 x/± 14b 462 x/÷ 1.5 169 x/÷ 20b
mm)
HbA1 (%) 10.6 3.0 10.4 2.1 12.4 3.8 9.2 2.4
a Mean arterial pressure (MAP), glomerular filtration rate (GFR),
renal plasma flow (RPF), filtration fraction (FF), renal vascular resis-
tance (RVR), glycosylated hemoglobin (HbA1), and urinary albumin
excretion (UAE) were determined before and after 12 weeks of captro-
pril therapy in patients with IDDM and microalbuminuria or clinical
nephropathy. Values are presented as mean SD except for UAE,
which is expressed by geometric mean x/+ confidence factor.
b p < 0.05.
Reductions in urinary albumin excretion were observed even in
the 2 patients whose blood pressure increased during captopril
administration. Although subtle changes in intrarenal hemody-
namics cannot be ruled out on the basis of the clearance
measurements, these results would be in accordance with a
direct action of ACE inhibitors on the glomerular membrane:
enhancing barrier size selectivity [53]. The clinical impact of
this antiproteinuric action, which appears to be unrelated to the
hypotensive effect, is a matter of current debate [54].
Choice of antihypertensive agents. Potential disadvantages
and advantages of particular antihypertensive agents used in
treating diabetic patients have been suggested but not com-
pletely established. Recent studies from different groups have
suggested a limitation in the use of diuretics in diabetic patients
because of the potential adverse effects of these agents. A
longitudinal study of 132 diabetic patients (86 with NIDDM and
46 with IDDM) assessed changes in renal function as related to
blood pressure, diabetic control, and the renin-angiotensin
system [55]. This study confirmed a strong association between
persistently elevated blood pressure and the rate of progression
of renal damage for both groups of diabetic patients. The most
dramatic finding was the association between the use of diuret-
ics and an escalation in the rate of decline in renal function,
especially in the patients with NIDDM. The hypertensive
patients with NIDDM who were treated with diuretics exhibited
a rate of renal loss, as estimated from the reciprocal of plasma
creatinine plotted as a function of time, of —0.018 0.015
dl/mg/month; in contrast, the hypertensive patients with
NIDDM who were treated with agents other than diuretics had
a value of +0.0015 0.006 dl/mg/month (P < 0.015). Compa-
rable differences were observed for the insulin-dependent
group, but the number of patients was too small to allow
statistically significant conclusions.
A subsequent study analyzing factors determining the mor-
tality rate over 6 years in 2366 patients with IDDM also showed
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that diuretic use was among a variety of predictors for de-
creased survival time [561. A more recent report analyzed the
risk factors for shortened life span among diabetic patients
receiving antihypertensive therapy [57]. Among 759 diabetics,
mostly with IDDM and normal renal function, studied for a
median time of 4.5 years, cardiovascular mortality was higher in
patients treated for hypertension than in the patients with
untreated hypertension. The higher mortality rate was primarily
due to the deaths of patients treated with diuretics alone, in
whom the cardiovascular mortality rate was 3.8 times higher
than that in patients with untreated hypertension. The explana-
tion for these data is elusive, and confirmation of these findings
in prospective trials is needed before these data can be trans-
lated into established clinical practice.
Angiotensin-converting-enzyme inhibitors, on the contrary,
may be particularly beneficial in diabetic patients with nephrop-
athy, because these agents not only control blood pressure but
also possess antialbuminuric properties that might afford better
renal protection in the long run. The ACE inhibitors therefore
might have a renoprotective effect [58]. Thus one study showed
better preservation of renal function with the ACE inhibitor
enalapril than with the beta-blocker metoprolol [59]. In this
prospective, open, randomized study, 40 hypertensive patients
with IDDM and clinical nephropathy including reduced renal
function were followed for 2.2 years. Antihypertensive treat-
ment included enalapril or metoprolol, usually combined with
furosemide. The reductions in blood pressure were of similar
magnitude with both drugs; however, enalapril, but not meto-
prolol, significantly decreased urinary protein excretion. In the
enalapril-treated group, the major decrease in glomerular filtra-
tion rate occurred in the first 6 months, probably because of
enalapril's effect on renal hemodynamics, but renal function
remained stable thereafter. At the end of the study, the rate of
the fall in GFR was lower in the enalapril-treated group than in
the metoprolol-treated group (2.0 mllminlyear versus 5.5 ml!
mm/year, respectively, P C 0.05). These results strongly sug-
gest that long-term treatment with enalapril affords better renal
protection than does metoprolol. The favorable metabolic pro-
file, together with its antihypertensive action and the correction
of renal hemodynamic alterations of diabetes, are offered by the
authors as explaining the better results obtained with enalapril.
Actually the favorable metabolic profile of ACE inhibitors
makes these drugs particularly attractive also for hypertensive
patients with NIDDM [60]. Obviously, the possibility that one
antihypertensive agent is more advantageous than others will
have to be tested in large series of patients and refined in
prospective long-term clinical trials before these limited albeit
existing results are considered conclusive.
Orthostatic hypotension in diabetics. Postural hypotension is
another disturbance of systemic blood pressure that affects
approximately 10% of the diabetic population. An orthostatic
fall in blood pressure is the most common clinical expression of
autonomic neuropathy involving the cardiovascular system
[61]. Blood pressure is maintained to a large extent by the
combined effect of three major neurohumoral pressor mecha-
nisms: the renin-angiotensin system, the sympathetic nervous
system, and arginine vasopressin (AVP). Diabetic patients
often have damaged peripheral sympathetic nerves and an
unresponsive renin-angiotensin system [62], so AVP would be
expected to play a major role in the maintenance of systemic
blood pressure in these patients. We analyzed this possibility in
16 patients with NIDDM who had mild to moderate (supine)
hypertension [63]. They were separated into two groups: the
Fig. 3. Variations in mean arterial pressure (A MAP) and urinary
albumin excretion (A UAE) induced by captopril (25 mg bid) for 12
weeks in 10 patients with insulin-dependent diabetes mellitus. Each
column refers to an individual patient.
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Fig. 4. Time course of mean arterial pressure (MAP) before and after
vasopressin inhibition (AVP-I) in the 3 subgroups of diabetic hyperten-
sive patients: 6 with autonomic insufficiency (group I, •), 4 with
orthostatic MAP fall only after A VP-I (group ha, A), and 6 with no
orthostatic MAP changes (group lib, D). Symbols (*, *) indicate
significant difference (P < 0.05). Abbreviations are: S, supine; U,
upright; Pre, before AVP-I; Post, after AVP-I. (Reproduced from Ref.
63 with permission.)
first comprised 6 patients with preexisting orthostatic hypoten-
sion (defined as an upright diastolic blood pressure decrease of
>10 mm Hg); the second had 10 patients without orthostatic
hypotension. We assessed AVP's role in the control of systemic
blood pressure by determining the mean arterial pressure
(MAP) responses to a specific V1 vasopressin receptor inhibitor
(AVP-I) [64]. Figure 4 shows the blood pressure responses to
upright posture before and after AVP-I administration. In
Group I, the average postural spontaneous blood pressure drop
of 20 mm Hg was accentuated to an average drop of 44 mm Hg
after the AVP-I. The 10 patients with no preexisting signs of
autonomic insufficiency displayed two distinct responses: 6 had
no orthostatic blood pressure changes either before or after
inhibition of AVP (Group lib), and 4, who also had no sponta-
neous orthostatic blood pressure changes, displayed a signifi-
cant orthostatic fall in arterial pressure, an average of 18 mm Hg
after AVP inhibition (Group ha). More detailed comparisons of
groups ha and lib showed no differences other than an altered
response to the Valsalva maneuver in the patients of group ha;
we therefore inferred that these patients had a mild autonomic
dysfunction. The only apparent hormonal difference between
groups I and II was the level of plasma renin activity, which
tended to be lower in group I. We concluded that AVP plays a
crucial role in preventing or minimizing postural hypotension in
diabetic patients. This role is even more important in patients
with autonomic dysfunction in whom the contribution of both
the renin-angiotensin system and the sympathetic nervous
system are diminished, whereas the pressor effectiveness of
vasopressin is greatly increased.
Orthostatic hypotension can be a disabling complication of
diabetes and represents a difficult medical problem. Nonphar-
macologic measures such as elastic stockings, orientation to
avoid abrupt rise from bed, and head-up tilt during sleep usually
are not sufficient to control this progressive condition in dia-
betic patients. The usual pharmacologic treatment of postural
hypotension includes either the administration of the mineralo-
corticoid 9-aipha-fluorohydrocortisone (together with a high
salt intake), or beta blockers, or a variety of other medications
(65). The use of 9-alpha-fluorohydrocortisone in diabetic pa-
tients is particularly troublesome because of the frequent asso-
ciation of postural hypotension with supine hypertension in
these patients. Beta blockers also are not the first-choice drugs
in this group because they can blunt hypoglycemic symptoms
and diminish blood perfusion, a particularly unwanted side
effect in this population, which has a high prevalence of
peripheral vascular disease. Thus, alternative therapeutic ap-
proaches are of particular interest for the treatment of postural
hypotension in diabetic patients. One such treatment was
prompted by the observation, in a case of severe orthostatic
hypotension due to extensive sympathectomy, that total plasma
dopamine levels that were higher than normal in the supine
position further increased in response to standing (66). Dopa-
minergic blockade with metoclopramide prevented the previ-
ously found postural increase in dopamine and improved the
orthostatic hypotension. The same group subsequently demon-
strated that an abnormally high total dopamine release follow-
ing the upright posture was a common pathophysiologic finding
in orthostatic hypotension of several causes, including diabetic
neuropathy (67). These authors postulated that increased do-
pamine release, which resulted in plasma concentrations in the
1—30 pmol/ml range, would decrease blood pressure via dopa-
minergic receptors and that this action would be inhibited by
metoclopramide (66). Prolonged beneficial effect was thought to
be due to an increase in plasma aldosterone released from
dopaminergic inhibitory control by metoclopramide, as demon-
strated by others (68). In a study on the acute hemodynamic
response to metoclopramide in patients with postural hypoten-
sion due to diabetic neuropathy, we showed that increased
peripheral resistance and not increased cardiac output explains
the beneficial effect of this dopaminergic antagonist, but we
were unable to determine the mechanism for the vasoconstric-
tion (69). Metoclopramide, however, has limitations in clinical
use, such as somnolence and Parkinson-like symptoms (person-
al observations).
We decided to test the effects of domperidone, a peripheral
dopaminergic antagonist of the DA2 dopamine receptors devoid
of central actions [70] in 9 patients with postural hypotension
secondary to diabetic neuropathy [71]. Acute and long-term
blood pressure responses to domperidone (DOMP) (10 mg
orally three times daily) were analyzed. Table 6 shows blood
pressure levels and humoral as well as renal effects during
upright posture before treatment and the same parameters in
the upright posture after 3 days of domperidone therapy. As
expected for these patients, the upright posture caused a
spontaneous reduction both in systolic and diastolic pressures.
The upright posture also caused an important and statistically
significant reduction in the creatinine clearance and the urinary
excretion of sodium and potassium; this change reflects renal
underperfusion in this position. A small but statistically signif-
icant increase in plasma renin activity and plasma aldosterone
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Table 6. Clinical and laboratory values before and after domperidone
therapy
Supine Upright
Control DOMP
SBP (mm Hg)a 132 13 75 22 89
DBP (mm Hg) 77 5 57 13 61 8
PRA (ng/ml/hr) 0,3 0.2 0.9 0.6' 1.21 1.2
PA (ngldl) 2.8 9.9 23.7 13.3' 22.7 17.5
UA (/.Lg/4 hr) 0.2 0.2 0.1 0.1 0.2 0.2
NE(p.g/4/zr) 4.9 4.1 3.6 3.1 6.4 7.9
DA (,cLg/4 hr) 39.4 45.7 34.3 22.2 75.2 120.1
PRL (ng/dl) 3.4 3.6 8.9 11.0 44•
UVNa (mEq/4 hr) 43.0 21.4 15.6 6.1' 29.2 17.0"
UVK (mEq/4 hr)
Ccr (mI/mm)
15.0 7.4
73.3 38.5
6.9 2.7'
41.6 11.0'
11.8 64b
59.6 32.2"
a Abbreviations: DOMP, domperidone; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure: PRA, plasma renin activity; PA,
plasma aldosterone; UA, urinary aldosterone excretion; NE, urinary
norepinephrine excretion; DA, urinary dopamine excretion; PRL,
plasma prolactin; UVNa, urinary sodium excretion; UVK, urinary
potassium excretion; Clr, creatinine clearance. NE, DA, PRL, UVNa,
UVK, and Cr were determined in the supine and upright posture before
treatment (control) and in the upright posture after 3 days of domperi-
done, 30 mg/day (DOMP). SBP and DBP values were obtained after 120
minutes in each posture.
b P < 0.05 control.
'P < 0.05 versus supine.
d p < 0.001 versus control.
also was observed. Small and not statistically significant varia-
tions were observed in the urinary excretion of aldosterone,
norepinephrine, epinephrine, and dopamine. Plasma prolactin
levels (measured as a marker of the dopaminergic blockade) did
not change, as expected for this phase of the study. These
results show that because of their diabetic neuropathy, these
patients could not stimulate the production of catecholamines
normally following a change from supine to upright posture.
After 3 days of domperidone therapy, a marked increase in
plasma prolactin levels, indicating the effectiveness of domp-
eridone-induced dopaminergic antagonism, was apparent. Also
the severity of the postural hypotension, especially regarding
the systolic pressure, improved. This improvement was accom-
panied by an increase in renal perfusion as reflected by the
increase in the creatinine clearance and the urinary excretion of
sodium and potassium. During this 3-day period, however,
domperidone did not alter the renin-angiotensin-aldosterone
system, nor did it change the urinary excretion of norepineph-
rine, epinephrine, or dopamine in response to upright posture.
Thus the one or more mechanisms through which domperidone
reduces the blood pressure fall in the upright posture appear not
to be mediated by these vasoconstrictor hormones, at least as
evaluated in our study. The long-term blood pressure response
to orthostasis during domperidone therapy is shown in Figure 5.
It is apparent that the drop in blood pressure after 2 minutes in
the upright posture was of smaller magnitude as of 7 to 15 days
of treatment. In 6 patients in whom blood pressure levels were
available for the entire duration of the study, the levels of
orthostatic blood pressure were higher than before domperi-
done therapy (P <0.001), persisted for the entire 6 months of
followup, and were not associated with a significant change in
supine blood pressure levels. This profile represents an advan-
tage of this form of treatment because most of these patients
have supine hypertension and most alternative treatments of
postural hypotension raise supine as well as upright blood
pressure. All patients had a noticeable improvement in the
symptoms related to postural hypotension. Domperidone is a
good therapeutic option for the treatment of orthostatic hypo-
tension in patients with diabetes.
Questions and answers
DR. OSWALDO Luis RAMOS (Professor of Medicine, Chief,
Department of Medicine, Escola Paulista de Medicina, São
Paulo, Brazil): How do you reconcile the fact that diuretics
decrease blood pressure and microalbuminuria and are thus
beneficial in hypertensive patients with the fact that diuretics
actually might increase the total mortality rate and the preva-
lence of renal disease in diabetic patients?
DR. RIBEIR0: This is an unsettled issue at this time. There is
no doubt that high blood pressure is a major risk factor for
diabetic renal disease and that it must be treated; several
studies have shown renal protection from lowering blood pres-
sure. In these studies, diuretics were used in association with
other antihypertensive agents, and we do not know what the
results would have been had these agents been used alone. The
tentative evidence to date is that they seem to be more
dangerous for diabetic patients when they are used alone. The
issue of whether diuretics have important deleterious side
effects—even for nondiabetic hypertensive patients.—is under
intense debate. In this latter group, as you know, it has been
suggested that the deleterious metabolic side effects of diuret-
ics, especially alterations in insulin action, glucose metabolism,
lipid levels, and electrolytes, can offset the advantages gained
through their antihypertensive effect. To date 3 studies in
diabetic patients have supported a limitation of diuretic use; one
demonstrated progression of nephropathy and two showed
increased mortality [55—57]. The explanation for these observa-
tions is not clear. However the same deleterious metabolic side
effect that affects nondiabetics, namely, diuretic-induced in-
creases in angiotensin II, could result in critical narrowing of
already compromised coronary arteries. Finally, diabetic pa-
tients with diuretic-induced low blood pressure could be at
particularly high risk for failure to autoregulate blood flow to
key organs due to concurrent autonomic neuropathy. Even
though these studies support a limitation on the use of diuretics
in diabetic patients, these data will have to be confirmed by
prospective clinical trials before their real meaning is com-
pletely understood.
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): You
mentioned that in your longitudinal studies, rats with strepto-
zotocin-induced diabetes mellitus and modest hyperglycemia
developed progressive increases in their blood pressure and
became hypertensive. As you know, evidence suggests that in
this model the increased filtered load of glucose stimulates
proximal sodium reabsorption via the brush-border sodium!
glucose cotransporter. Have you studied the impact of salt
restriction on the level of the animal's blood pressure?
DR. RIBEm0: Yes we did. Blood pressure levels in rats with
streptozotocin-induced diabetes receiving a low-sodium diet for
6 weeks were lower than levels in diabetic rats receiving a
normal sodium diet (123 1 mm Hg versus 138 1 mm Hg,
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Fig. 5. Mean blood pressure values during
domperidone therapy. Bars represent systolic
(top) and diastolic (bottom) blood pressure
levels in supine (open bars) and after 2
minutes of orthostatism (shaded bars). * D <
0.001 compared with baseline. (Reproduced
from Ref. 71 with permission.)
respectively; n = 6, P < 0.005). However, the blood pressure in
these low-sodium-treated diabetic rats were still significantly
higher than levels in control rats. Thus, a low-salt diet only
partially prevents the appearance of high blood pressure in
diabetic rats.
Da. JosE LOPES DE FARIA (Assistant Professor of Medicine,
Nephrology Division, Escola de Medicina da Universidade de
Campinas, Campinas, Brazil): One of the important aspects of
diabetic nephropathy and associated hypertension in humans is
that it only affects 30% to 40% of patients with IDDM. All rats
with streptozotocin-induced diabetes develop proteinuria and
hypertension, however. Do you think this rat model is a good
model for studying the diabetic nephropathy and hypertension
that occur in humans?
DR. RIBEIR0: The clinical relevance of animal models is
always an important and controversial issue. However, rats
with long-standing chemically induced diabetes develop renal
morphologic changes that are similar to those observed in
diabetic patients. Furthermore, the beneficial results of the
correction of intraglomerular hemodynamic abnormalities de-
tected in streptozotocin-induced diabetes in rats [46] have
provided the basis for therapeutic approaches in humans that
appear to confirm the clinical relevance of this model.
DR. MADIAS: Is there a consensus as to whether microalbu-
minuria versus elevation in blood pressure, albeit in the normal
range, appears first? Has 24-hour blood pressure monitoring
been employed as a better index of blood pressure in studying
the evolution of diabetic nephropathy?
DR. RIBEIR0: Most of the available data indicate that blood
pressure elevation and microalbuminuria occur concomitantly.
But no consensus exists as to whether the elevation of blood
pressure precedes, accompanies, or follows the increase in
urinary albumin excretion. Yes, the correlation between uri-
nary albumin excretion and 24-hour blood pressure values is
better than that between urinary albumin excretion and clinical
blood pressure values; 24-hour blood pressure monitoring pro-
vides more relevant information about the role of blood pres-
sure in the natural history of diabetic nephropathy [721.
DR. EMIL SABBAGA (Professor of Medicine, Kidney Trans-
plant Unit, Faculdade de Medicina da Universidade de São
Paulo, São Paulo): Postural hypotension in diabetic patients
diminishes and disappears a short time after a kidney trans-
plant. How do you explain that change?
DR. RIB EIR0: After kidney transplantation, elimination of the
uremic state can improve nerve conduction, and the renin-
angiotensin system often becomes more active. We therefore
can expect an improved vasoconstrictor response to upright
posture. Also, the general improvement in tissue perfusion that
follows renal transplantation should enhance the efficiency of
systemic blood pressure control mechanisms. In the long run,
however, correction of uremia through successful renal trans-
plantation [73], even when combined with pancreatic transplan-
tation [74], does not halt the progression of diabetic neuropa-
thy, and recurrence of postural hypotension is to be expected.
DR. MADIAS: Regarding your studies utilizing a V1 antago-
nist, is this agent free of intrinsic hemodynamic effects?
DR. RIBETRO: We documented no significant intrinsic activity
of our AVP antagonist in our human studies. However, we have
not tested our antagonist in the absence of endogenous AVP, in
patients with diabetes insipidus, for instance.
DR. MADIAS: How much do we know about domperidone's
ability to increase upright blood pressure levels?
DR. RIBEIR0: We were unable to determine the mechanism
by which domperidone reduces the fall in blood pressure during
upright posture. We could demonstrate no changes in the
activity of the renin-angiotensin system; this result contrasts
with our observation that the dopaminergic antagonism with
metoclopramide increases plasma renin activity and plasma
aldosterone [69]. In our work, domperidone did not increase
vascular and adrenal responsiveness to angiotensin II, nor was
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it associated with an augmented urinary excretion of catechola-
mines. We do know that dopamine, acting through its DA2
presynaptic receptors, inhibits norepinephrine release from
noradrenergic terminals [75]. Antagonizing this inhibitory ac-
tion of domperidone might enhance norepinephrine release and,
through this mechanism, improve orthostatic hypotension.
DR. MADIAS: As a group, do diabetic patients with ortho-
static hypotension differ from those without this complication in
clinical characteristics, baseline levels of vasoactive hormones,
or number of adrenoceptors? Are there differences between
diabetic orthostatic hypotension versus other types, for exam-
ple, the Shy-Drager syndrome, in terms of hemodynamic re-
sponse, response to Valsalva maneuver, adrenoceptors, etc?
DR. RIBEIR0: Diabetic patients with orthostatic hypotension
usually have long-standing diabetes, blunted baroreceptor re-
flexes [76], low levels of circulating catecholamines [77], lower
plasma renin activity, especially in orthostasis [78], and an
increased urinary dopamine/norepinephrine ratio [67]. Some
diabetic patients with postural hypotension, however, do not
have lower levels of plasma norepinephrine, and in these
patients vascular alpha-adrenergic receptor function can be
diminished due to a loss of number and/or sensitivity. The
patient thus is unable to produce an adequate vasopressor
response [62]. I am not aware that one can differentiate the
postural hypotension of diabetes from that of other causes by
any characteristic hemodynamic pattern, response to auto-
nomic nervous system stimulatory maneuvers, or peculiar
adrenoceptor alteration. The diabetic orthostatic hypotension is
unique in terms of its pathophysiology; this type of autonomic
insufficiency appears to be caused by the accumulation of
sorbitol, a metabolic consequence of hyperglycemia [79].
DR. MADIAs: Are there any observations on the levels of
ANP during recumbency and orthostasis in diabetic patients
with orthostatic hypotension?
DR. RIBEIR0: I do not know of any data on ANP in diabetic
patients with orthostatic hypotension, although ANP levels
were increased in nonketotic diabetic patients, and this increase
paralleled increases in plasma glucose [80].
DR. LOPES DE FARIA: I have a question about the first patient
presented here. He has IDDM, clinical proteinuria, hyperfiltra-
tion (GFR, 190 mI/mm), and mild hypertension. This combina-
tion of problems is unusual. What is your opinion about this
particular subgroup of patients with IDDM who present with
proteinuria, hyperfiltration, and "normal" blood pressure?
DR. RIBEIR0: I agree that clinical proteinuria in diabetic
patients usually is accompanied by a diminution in renal func-
tion and a rise in blood pressure. There is great individual
variability, however, and a patient also could have proteinuria
and preserved renal function, because glomerular filtration rate
and increased glomerular permeability to protein are deter-
mined by different mechanisms. This patient did not have
normal blood pressure, however. Actually he was hyperten-
sive: his blood pressure was 150/100 mm Hg, even though he
was taking chlorthalidone.
DR. R0GERI0 ANDRADE MULINARI (Associate Professor of
Medicine, Nephrology Division, Escola Paulista de Medicina,
São Paulo): I'd like to return to your comments regarding the
difficulty in choosing medication for hypertensive diabetic
patients. Would you comment on the suggestion for pharmaco-
logic antihypertensive treatment of normotensive, microalbu-
minuric diabetic patients?
DR. RIBEIR0: Not enough data have been accumulated to
support the possibility that pharmacologic treatment of normo-
tensive, microalbuminuric diabetic patients would prevent or
delay diabetic nephropathy. Thus, clinicians currently are ad-
vised not to treat these patients.
DR. MADIAS: What are your guidelines regarding goal blood
pressure levels in younger and older diabetic hypertensive
patients?
DR. RIBEIR0: We lack large, well-designed, controlled inter-
ventional studies of blood pressure reduction in diabetic hyper-
tensive patients. It is therefore difficult to arrive at firm conclu-
sions about target blood pressure levels. But let me provide a
simple answer to your question. A diastolic blood pressure of 85
mm Hg would be a good therapeutic goal for young diabetic
patients (mainly those with IDDM under the age of 30 years),
because no evidence indicates that a lower diastolic blood
pressure further reduces cardiovascular risk [81]. For older
patients (mainly those with NIDDM), the World Health Orga-
nization Multinational Study of Vascular Disease in Diabetics
showed no clear benefit of reducing diastolic blood pressure
lower than 95 mm Hg [81]. Arriving at a goal blood pressure
level in the elderly also must take into account how the patient
tolerates the lower blood pressure level; obviously, treatment-
associated symptoms should be avoided or minimized.
DR. GERARD MALNIC (Professor of Physiology, Chairman,
Instituto de Ciencias Biomedicas, Universidade de São Paulo,
São Paulo): You referred to alterations in sodium/lithium and
sodium/hydrogen exchange in diabetic nephropathy. Is there
any information about which isoform of Na/H exchange
(basolateral or brush-border membrane) is involved? Does this
change affect the systemic acid-base balance?
DR. RIBEIR0: Although this fact is not clearly established, the
recently cloned human sodium/hydrogen exchanger probably
corresponds to the basolateral isoform in the proximal tubule
and the ileal villus cell [82—84]. This isoform likely represents
the "housekeeping" Na/H exchanger that is important for
the regulation of intracellular pH and cell volume but does not
contribute to transepithelial bicarbonate (proton) transport (bi-
carbonate reabsorption). Although its role in overall acid-base
balance remains undefined, it is of interest that recent studies
have shown that metabolic, and possibly respiratory, acidosis
increases the mRNA levels of this transporter in rat renal cortex
and renal epithelial cell lines [85, 86]. As yet, the brush-border
Na/H exchanger has not been cloned.
DR. MADIAS: You cited evidence suggesting that increased
angiotensin II might be a risk factor for diabetic nephropathy.
Given that both in clinical and experimental diabetes mellitus
the plasma renin-angiotensin system is either normal or sup-
pressed, were you referring to the status of the vascular or
intrarenal renin-angiotensin system?
DR. RIBEIRO: No. The reference was to the plasma renin-
angiotensin system. A longitudinal study using multiple regres-
sion techniques found that the plasma level of angiotensin II
was an independent risk factor for diabetic nephropathy [551. I
should stress, however, that that was the only study that made
this suggestion and that most patients in the study were
hypertensive and were receiving diuretics.
DR. HoRAclo AJZEN (Professor of Medicine and Chief,
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Nephrology Division, Escola Paulista de Medicina, São
Paulo): What is the importance, if any, of a low-protein diet in
diabetic normotensive patients? Could a low-protein diet be
used instead of ACE inhibitors?
DR. RIBEIR0: Dietary protein restriction in normotensive
diabetic patients effectively diminished hyperfiltration and uri-
nary albumin excretion in short-term studies [87]. No long-term
observations are yet available that would allow us to conclude
whether that approach would delay or prevent overt diabetic
nephropathy or how it would compare with ACE inhibitors.
DR. MADIAS: Angiotensin-converting-enzyme inhibitors in-
crease insulin sensitivity in patients with essential hypertension
[881. Is there hard evidence that these drugs have a similar
effect in patients with NIDDM?
DR. RIBEIR0: The data indicate that ACE inhibitors promote
a small increase in insulin sensitivity in patients with NIDDM.
Captopril acutely increases both whole-body glucose uptake
during euglycemic insulin clamp and forearm glucose uptake
[891. Two randomized controlled clinical studies over 2 and 4
months have reported marginal but significant decreases in
glycosylated hemoglobin in patients with NIDDM following
angiotensin-converting-enzyme inhibition [90, 911.
DR. MADIAS: You referred to the potential nephroprotective
advantage of ACE inhibitors in diabetes mellitus. I would like to
press you on this issue. In my judgment, there is still no
definitive clinical evidence that the antiproteinuric effect of
these agents is greater than that of other antihypertensive
drugs. Moreover, it remains to be shown whether the reduction
in microalbuminuria will translate into protection from clinical
nephropathy,
DR. RIBEIR0: There is one difference: in diabetic nephropa-
thy, ACE inhibitors diminish urinary protein excretion even
when they do not lower blood pressure. To my knowledge, that
property is not shared with any other antihypertensive agents.
With other antihypertensive agents, the antiproteinuric effect
directly correlates with the fall in blood pressure. Thus, the data
indicate that ACE inhibitors exhibit antiproteinuric actions
through mechanisms independent of their antihypertensive ac-
tion. I agree with you that all antihypertensive agents have a
similar antiproteinuric effect when blood pressure is appropri-
ately reduced. I also agree that we don't have enough data to
assume that decreases in protein excretion will necessarily be
followed by a prevention or delay in overt diabetic nephropa-
thy. We will have to wait for long-term prospective trials to
have this answer.
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